BACKGROUND: There is debate about the value of assessing levels of C-reactive protein (CRP) and other biomarkers of inflammation for the prediction of first cardiovascular events. METHODS: We analyzed data from 52 prospective studies that included 246,669 participants without a history of cardiovascular disease to investigate the value of adding CRP or fibrinogen levels to conventional risk factors for the prediction of cardiovascular risk. We calculated measures of discrimination and reclassification during follow-up and modeled the clinical implications of initiation of statin therapy after the assessment of CRP or fibrinogen. RESULTS: The addition of information on high-density lipoprotein cholesterol to a prognostic model for cardiovascular disease that included age, sex, smoking status, blood pressure, history of diabetes, and total cholesterol level increased the C-index, a measure of risk discrimination, by 0.0050. The further addition to this model of information on CRP or fibrinogen increased the C-index by 0.0039 and 0.0027, respectively (P<0.001), and yielded a net reclassification improvement of 1.52% and 0.83%, respectively, for the predicted 10-year risk categories of "low" (<10%), "intermediate" (10% to <20%), and "high" (≥20%) (P<0.02 for both comparisons). We estimated that among 100,000 adults 40 years of age or older, 15,025 persons would initially be classified as being at intermediate risk for a cardiovascular event if conventional risk factors alone were used to calculate risk. Assuming that statin therapy would be initiated in accordance with Adult Treatment Panel III guidelines (i.e., for persons with a predicted risk of ≥20% and for those with certain other risk factors, such as diabetes, irrespective of their 10-year predicted risk), additional targeted assessment of CRP or fibrinogen levels in the 13,199 remaining participants at intermediate risk could help prevent approximately 30 additional cardiovascular events over the course of 10 years. CONCLUSIONS: In a study of people without known cardiovascular disease, we estimated that under current treatment guidelines, assessment of the CRP or fibrinogen level in people at intermediate risk for a cardiovascular event could help prevent one additional event over a period of 10 years for every 400 to 500 people screened. (Funded by the British Heart Foundation and others.).
BACKGROUND: There is debate about the value of assessing levels of C-reactive protein (CRP) and other biomarkers of inflammation for the prediction of first cardiovascular events. METHODS: We analyzed data from 52 prospective studies that included 246,669 participants without a history of cardiovascular disease to investigate the value of adding CRP or fibrinogen levels to conventional risk factors for the prediction of cardiovascular risk. We calculated measures of discrimination and reclassification during follow-up and modeled the clinical implications of initiation of statin therapy after the assessment of CRP or fibrinogen. RESULTS: The addition of information on high-density lipoprotein cholesterol to a prognostic model for cardiovascular disease that included age, sex, smoking status, blood pressure, history of diabetes, and total cholesterol level increased the C-index, a measure of risk discrimination, by 0.0050. The further addition to this model of information on CRP or fibrinogen increased the C-index by 0.0039 and 0.0027, respectively (P<0.001), and yielded a net reclassification improvement of 1.52% and 0.83%, respectively, for the predicted 10-year risk categories of "low" (<10%), "intermediate" (10% to <20%), and "high" (≥20%) (P<0.02 for both comparisons). We estimated that among 100,000 adults 40 years of age or older, 15,025 persons would initially be classified as being at intermediate risk for a cardiovascular event if conventional risk factors alone were used to calculate risk. Assuming that statin therapy would be initiated in accordance with Adult Treatment Panel III guidelines (i.e., for persons with a predicted risk of ≥20% and for those with certain other risk factors, such as diabetes, irrespective of their 10-year predicted risk), additional targeted assessment of CRP or fibrinogen levels in the 13,199 remaining participants at intermediate risk could help prevent approximately 30 additional cardiovascular events over the course of 10 years. CONCLUSIONS: In a study of people without known cardiovascular disease, we estimated that under current treatment guidelines, assessment of the CRP or fibrinogen level in people at intermediate risk for a cardiovascular event could help prevent one additional event over a period of 10 years for every 400 to 500 people screened. (Funded by the British Heart Foundation and others.).
Authors: John Danesh; Sarah Lewington; Simon G Thompson; Gordon D O Lowe; Rory Collins; J B Kostis; A C Wilson; A R Folsom; K Wu; M Benderly; U Goldbourt; J Willeit; S Kiechl; J W G Yarnell; P M Sweetnam; P C Elwood; M Cushman; B M Psaty; R P Tracy; A Tybjaerg-Hansen; F Haverkate; M P M de Maat; F G R Fowkes; A J Lee; F B Smith; V Salomaa; K Harald; R Rasi; E Vahtera; P Jousilahti; J Pekkanen; R D'Agostino; W B Kannel; P W F Wilson; G Tofler; C L Arocha-Piñango; A Rodriguez-Larralde; E Nagy; M Mijares; R Espinosa; E Rodriquez-Roa; E Ryder; M P Diez-Ewald; G Campos; V Fernandez; E Torres; R Marchioli; F Valagussa; A Rosengren; L Wilhelmsen; G Lappas; H Eriksson; P Cremer; D Nagel; J D Curb; B Rodriguez; K Yano; J T Salonen; K Nyyssönen; T-P Tuomainen; B Hedblad; P Lind; H Loewel; W Koenig; T W Meade; J A Cooper; B De Stavola; C Knottenbelt; G J Miller; J A Cooper; K A Bauer; R D Rosenberg; S Sato; A Kitamura; Y Naito; T Palosuo; P Ducimetiere; P Amouyel; D Arveiler; A E Evans; J Ferrieres; I Juhan-Vague; A Bingham; H Schulte; G Assmann; B Cantin; B Lamarche; J-P Després; G R Dagenais; H Tunstall-Pedoe; M Woodward; Y Ben-Shlomo; G Davey Smith; V Palmieri; J L Yeh; A Rudnicka; P Ridker; F Rodeghiero; A Tosetto; J Shepherd; I Ford; M Robertson; E Brunner; M Shipley; E J M Feskens; D Kromhout; A Dickinson; B Ireland; K Juzwishin; S Kaptoge; S Lewington; A Memon; N Sarwar; M Walker; J Wheeler; I White; A Wood Journal: JAMA Date: 2005-10-12 Impact factor: 56.272
Authors: Alexander Thompson; Pei Gao; Lia Orfei; Sarah Watson; Emanuele Di Angelantonio; Stephen Kaptoge; Christie Ballantyne; Christopher P Cannon; Michael Criqui; Mary Cushman; Albert Hofman; Chris Packard; Simon G Thompson; Rory Collins; John Danesh Journal: Lancet Date: 2010-05-01 Impact factor: 79.321
Authors: N Sarwar; P Gao; S R Kondapally Seshasai; R Gobin; S Kaptoge; E Di Angelantonio; E Ingelsson; D A Lawlor; E Selvin; M Stampfer; C D A Stehouwer; S Lewington; L Pennells; A Thompson; N Sattar; I R White; K K Ray; J Danesh Journal: Lancet Date: 2010-06-26 Impact factor: 202.731
Authors: Gary L Myers; Robert H M Christenson; Mary Cushman; Christie M Ballantyne; Gerald R Cooper; Christine M Pfeiffer; Scott M Grundy; Darwin R Labarthe; Daniel Levy; Nader Rifai; Peter W F Wilson Journal: Clin Chem Date: 2008-12-23 Impact factor: 8.327
Authors: J Danesh; S Erqou; M Walker; S G Thompson; R Tipping; C Ford; S Pressel; G Walldius; I Jungner; A R Folsom; L E Chambless; M Knuiman; P H Whincup; S G Wannamethee; R W Morris; J Willeit; S Kiechl; P Santer; A Mayr; N Wald; S Ebrahim; D A Lawlor; J W G Yarnell; J Gallacher; E Casiglia; V Tikhonoff; P J Nietert; S E Sutherland; D L Bachman; J E Keil; M Cushman; B M Psaty; R P Tracy; A Tybjaerg-Hansen; B G Nordestgaard; R Frikke-Schmidt; S Giampaoli; L Palmieri; S Panico; D Vanuzzo; L Pilotto; L Simons; J McCallum; Y Friedlander; F G R Fowkes; A J Lee; F B Smith; J Taylor; J Guralnik; C Phillips; R Wallace; D Blazer; K T Khaw; J H Jansson; C Donfrancesco; V Salomaa; K Harald; P Jousilahti; E Vartiainen; M Woodward; R B D'Agostino; P A Wolf; R S Vasan; M J Pencina; E M Bladbjerg; T Jorgensen; L Moller; J Jespersen; R Dankner; A Chetrit; F Lubin; A Rosengren; L Wilhelmsen; G Lappas; H Eriksson; C Bjorkelund; P Cremer; D Nagel; R Tilvis; T Strandberg; B Rodriguez; L M Bouter; R J Heine; J M Dekker; G Nijpels; C D A Stehouwer; E Rimm; J Pai; S Sato; H Iso; A Kitamura; H Noda; U Goldbourt; V Salomaa; J T Salonen; K Nyyssönen; T-P Tuomainen; D Deeg; J L Poppelaars; T Meade; J Cooper; B Hedblad; G Berglund; G Engstrom; A Döring; W Koenig; C Meisinger; W Mraz; L Kuller; R Selmer; A Tverdal; W Nystad; R Gillum; M Mussolino; S Hankinson; J Manson; B De Stavola; C Knottenbelt; J A Cooper; K A Bauer; R D Rosenberg; S Sato; Y Naito; I Holme; H Nakagawa; H Miura; P Ducimetiere; X Jouven; C Crespo; M Garcia-Palmieri; P Amouyel; D Arveiler; A Evans; J Ferrieres; H Schulte; G Assmann; J Shepherd; C Packard; N Sattar; B Cantin; B Lamarche; J-P Després; G R Dagenais; E Barrett-Connor; D Wingard; R Bettencourt; V Gudnason; T Aspelund; G Sigurdsson; B Thorsson; M Trevisan; J Witteman; I Kardys; M Breteler; A Hofman; H Tunstall-Pedoe; R Tavendale; G D O Lowe; Y Ben-Shlomo; B V Howard; Y Zhang; L Best; J Umans; A Onat; T W Meade; I Njolstad; E Mathiesen; M L Lochen; T Wilsgaard; J M Gaziano; M Stampfer; P Ridker; H Ulmer; G Diem; H Concin; F Rodeghiero; A Tosetto; E Brunner; M Shipley; J Buring; S M Cobbe; I Ford; M Robertson; Y He; A M Ibanez; E J M Feskens; D Kromhout; R Collins; E Di Angelantonio; S Kaptoge; S Lewington; L Orfei; L Pennells; P Perry; K Ray; N Sarwar; M Scherman; A Thompson; S Watson; F Wensley; I R White; A M Wood Journal: Eur J Epidemiol Date: 2007-09-18 Impact factor: 8.082
Authors: Anna Maria Gori; Betti Giusti; Benedetta Piccardi; Patrizia Nencini; Vanessa Palumbo; Mascia Nesi; Antonia Nucera; Giovanni Pracucci; Paolina Tonelli; Eleonora Innocenti; Alice Sereni; Elena Sticchi; Danilo Toni; Paolo Bovi; Mario Guidotti; Maria Rosaria Tola; Domenico Consoli; Giuseppe Micieli; Rossana Tassi; Giovanni Orlandi; Maria Sessa; Francesco Perini; Maria Luisa Delodovici; Maria Luisa Zedde; Francesca Massaro; Rosanna Abbate; Domenico Inzitari Journal: J Cereb Blood Flow Metab Date: 2017-03-07 Impact factor: 6.200
Authors: Catherine M Brown; Stephen T Turner; Kent R Bailey; Thomas H Mosley; Sharon L R Kardia; Heather J Wiste; Iftikhar J Kullo; Vesna D Garovic Journal: J Hypertens Date: 2013-11 Impact factor: 4.844
Authors: Seamus P Whelton; Probal Roy; Brad C Astor; Lin Zhang; Ron C Hoogeveen; Christie M Ballantyne; Josef Coresh Journal: Am J Epidemiol Date: 2013-09-10 Impact factor: 4.897
Authors: Mahmoud Al Rifai; Andrea L C Schneider; Alvaro Alonso; Nisa Maruthur; Christina M Parrinello; Brad C Astor; Ron C Hoogeveen; Elsayed Z Soliman; Lin Y Chen; Christie M Ballantyne; Marc K Halushka; Elizabeth Selvin Journal: J Diabetes Complications Date: 2014-11-25 Impact factor: 2.852